Compounds that block the production of damaging molecules might shed light on their role in disease—and lead to new therapies.

The cause of a rare, inherited, often fatal kidney disease in many patients remained elusive for years, despite multiple attempts to solve the mystery. Then in 2012, a team of researchers cracked some of the unsolved cases in just six weeks.

Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.

Industry labs find that, contrary to earlier evidence, KRAS-driven tumors are not addicted to autophagy.